[Clinical trial of UFT in malignancies--an analysis of 337 patients. Co-operative Group for Clinical Study of UFT].
Clinical phase II trial of UFT (4:1 mixture of 5-Fu and FT-207) prepared by Jinan Pharmaceutical Company was carried out cooperatively from 1984-1985. In 337 patients treated, 289 received UFT alone. The drug contains 50mg FT 207 per tablet. The dose given was #4, T. i. d. The total dose ranged from 8.4 g to 75.5 g in 6-8 weeks, majority of patients received 20-40 g. Complete remission was obtained in 7 patients (2.4%), while partial remission in 65 (22.5%), stable in 158 (54.7%) and progression in 59 (20.4%). Data showed that favorable results were observed in stomach cancer, esophageal cancer, rectum and colon cancer, and breast cancer. Excellent results were obtained in nasopharyngeal cancer with UFT in combination with irradiation. The gastro-intestinal tract reaction was mild, and bone marrow depression was observed in less than 15% of all patients treated. In conclusion, UFT may become an useful means in the management of common malignancies.